
News|Articles|June 20, 2024
Emerging Biosimilars and the Importance of Identifying Experienced Providers
Author(s)PurpleLab
Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Trending on Applied Clinical Trials Online
1
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
2
ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma
3
One Clinical: Working Together to Advance Trial Collaboration
4
Closing the Dead Time Gap in Clinical Data: Q&A with Raviv Pryluk, PhaseV
5